เอกสารอ้างอิง :
1. MIMS Online Thailand. 2020. Available from: http://www.mims.com/thailand/drug/info/?type=brief
2. Hesch K. Agents for treatment of overactive bladder: a therapeutic class review. Proc (Bayl Univ Med Cent). 2007;20(3):307–314. doi:10.1080/08998280.2007.11928310.
3. Lexi-Comp, Inc. Urodynamic evaluation of women with incontinence. Drug information. [Online]. Available from: UpToDate online;2020. [cited 2020,Feb,15]
4. Lexi-Comp, Inc. Drug information. [Online]. Available from: UpToDate online;2020. [cited 2020,Feb,15]
5. Doroshyenko O, Jetter A, Odenthal KP, Fuhr U. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet (2005) 44: 701-720
6. Hulya D. What is the success of drug treatment in urge urinary incontinence? What should be measured?. Arch Gynecol Obstet (2013) 287:511–518. Doi: 10.1007/s00404-012-2596-8.
7. Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998;81(6):801–810.
8. Halaska M, Ralph G, Wiedemann A, Primus G, Ballering-Bruhl B, Hofner K, Jonas U. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003;20(6):392–399.
9. Hashim H, Abrams P. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. Drugs 2004;64(15):1643–1656.
10. Trospium chloride (Sanctura): another anticholinergic for overactive bladder. Med Lett Drugs Ther 2004;46:63–64.